Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing Pseudomonas aeruginosa: insights from the hollow-fiber infection model.
Montero MM, Domene-Ochoa S, Prim N, Ferola E, López-Causapé C, Echeverria D, Morisaki MFA, Vega-Toribio V, Sorlí L, Luque S, Padilla E, Oliver A, Horcajada JP. Montero MM, et al. Infect Dis (Lond). 2025 Jan;57(1):81-88. doi: 10.1080/23744235.2024.2396882. Epub 2024 Aug 30. Infect Dis (Lond). 2025. PMID: 39212630
New Predictive Equation for the Estimation of Plasma Concentrations of Formed Colistin in Patients Treated With Colistimethate Sodium for Multidrug-Resistant Gram-Negative Bacterial Infections.
Luque S, Sorlí L, Li J, Fernández-Sala X, Berenguer N, Colominas-González E, Benítez-Cano A, Montero MM, Subirana I, Prim N, García-Paricio R, Horcajada JP, Grau S. Luque S, et al. Among authors: montero mm. Ther Drug Monit. 2024 Oct 1;46(5):594-602. doi: 10.1097/FTD.0000000000001216. Epub 2024 Jul 9. Ther Drug Monit. 2024. PMID: 38984536
A case-control study of the clinical and economic impact of infections caused by Carbapenemase-producing Enterobacterales (CPE).
López Montesinos I, Carot-Coll A, Montero MM, Sorli Redó L, Siverio-Parès A, Esteban-Cucó S, Durán X, Gomez-Zorrilla S, Horcajada JP. López Montesinos I, et al. Among authors: montero mm. Infection. 2024 Dec;52(6):2241-2252. doi: 10.1007/s15010-024-02268-z. Epub 2024 May 3. Infection. 2024. PMID: 38700659 Free PMC article.
Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy.
Royo-Cebrecos C, Laporte-Amargós J, Peña M, Ruiz-Camps I, Garcia-Vidal C, Abdala E, Oltolini C, Akova M, Montejo M, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Morales HMP, Brunel AS, García E, Isler B, Kern WV, Palacios-Baena ZR, de la Calle GM, Montero MM, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmatii P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Carratalà J, Gudiol C; IRONIC Study Group. Royo-Cebrecos C, et al. Among authors: montero mm. Microorganisms. 2024 Mar 30;12(4):705. doi: 10.3390/microorganisms12040705. Microorganisms. 2024. PMID: 38674650 Free PMC article.
Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID).
Horcajada JP, Aldonza R, Real M, Castañeda-Espinosa S, Sendra E, Gomez-Junyent J, López-Montesinos I, Gómez-Zorrilla S, Briansó S, Duran-Taberna M, Fernández A, Tarragó C, Auguet-Quintillá T; COVID-MAR Research group; COVID-HJ23 group. Horcajada JP, et al. Pneumonia (Nathan). 2024 Feb 25;16(1):3. doi: 10.1186/s41479-023-00124-6. Pneumonia (Nathan). 2024. PMID: 38402214 Free PMC article.
Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa.
Sorlí L, Luque S, Li J, Benítez-Cano A, Fernández X, Prim N, Vega V, Gómez-Junyent J, López-Montesinos I, Gómez-Zorrilla S, Montero MM, Grau S, Horcajada JP. Sorlí L, et al. Among authors: montero mm. Microbiol Spectr. 2023 Dec 12;11(6):e0296723. doi: 10.1128/spectrum.02967-23. Epub 2023 Nov 9. Microbiol Spectr. 2023. PMID: 37943035 Free PMC article.
Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria.
Fresán D, Luque S, Benítez-Cano A, Sorlí L, Montero MM, De-Antonio M, Vega V, Roberts JA, Horcajada JP, Grau S. Fresán D, et al. Among authors: montero mm. J Antimicrob Chemother. 2023 Dec 1;78(12):2810-2815. doi: 10.1093/jac/dkad296. J Antimicrob Chemother. 2023. PMID: 37823445
Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: a clinical narrative review.
Echeverria-Esnal D, Sorli L, Navarrete-Rouco ME, Prim N, Barcelo-Vidal J, Conde-Estévez D, Montero MM, Martin-Ontiyuelo C, Horcajada JP, Grau S. Echeverria-Esnal D, et al. Among authors: montero mm. Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):759-775. doi: 10.1080/14787210.2023.2223977. Epub 2023 Jun 14. Expert Rev Anti Infect Ther. 2023. PMID: 37294450 Review.
Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients.
Montero MM, Hardy-Werbin M, Gonzalez-Gallardo S, Torres E, Rueda R, Hannet I, Kirk JT, Yager TD, Navalkar K, Arenas MDM, Arietta-Aldea I, Castañeda S, Gómez-Junyent J, Gómez-Zorrilla S, Guerri-Fernandez R, Sanchez-Martinez F, López-Montesinos I, Pelegrín I, Sendra E, Sorlí L, Villar-García J, Bellosillo B, Horcajada JP. Montero MM, et al. Sci Rep. 2023 Jan 18;13(1):944. doi: 10.1038/s41598-023-28178-y. Sci Rep. 2023. PMID: 36653401 Free PMC article.
47 results